Douglas Giordano
Chief Executive Officer presso ANACOR PHARMACEUTICALS INC
Patrimonio netto: 138 730 $ in data 31/03/2024
Profilo
Douglas Ernest Giordano is currently the Chief Executive Officer at Anacor Pharmaceuticals LLC, the President, Treasurer & Director at Array BioPharma, Inc., the President & Director at FoldRx.
Pharmaceuticals LLC, the Director at ViiV Healthcare Ltd., the Managing Director at Perceptive Advisors (Private Equity), the Director at Cerevel Therapeutics LLC, the Independent Director at Cerevel Therapeutics Holdings, Inc., the Director at Cerevel Therapeutics, Inc., the Independent Director at Panacea Acquisition Corp.
II, the President at Encysive Pharmaceuticals, Inc., the Vice President at Icagen, Inc., and an Advisor at New Rhein Healthcare Investors.
Previously, Mr. Giordano worked as the Director at ICU Medical, Inc., the Director at KP Pharmaceuticals LLC, the Director at Zoetis, Inc., the President, Treasurer & Director at Medivation LLC (California), the Director at Viatris, Inc., and the Senior VP-Worldwide Business Development at Pfizer Inc. He also served as the President at Serenex, Inc.Mr. Giordano received his undergraduate degree from Duke University and his MBA from Johnson Graduate School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/01/2024 | 3 282 ( 0.00% ) | 138 730 $ | 31/03/2024 |
Posizioni attive di Douglas Giordano
| Società | Posizione | Inizio |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Chief Executive Officer | 24/06/2016 |
| ARRAY TECHNOLOGIES, INC. | President | 30/07/2019 |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Director/Board Member | 01/09/2018 |
| PANACEA ACQUISITION CORP. II | Director/Board Member | 06/04/2021 |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | President | 03/04/2008 |
New Rhein Healthcare Investors
 New Rhein Healthcare Investors Investment ManagersFinance New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania. | Consultant / Advisor | - |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | Private Equity Investor | 01/04/2021 |
| Duke University School of Medicine | Corporate Officer/Principal | - |
Cerevel Therapeutics LLC
 Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | Director/Board Member | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Precedenti posizioni note di Douglas Giordano
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di Douglas Giordano
| Duke University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| ICU MEDICAL, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| ZOETIS INC. | Health Technology |
| VIATRIS INC. | Health Technology |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Aziende private | 14 |
|---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
KP Pharmaceuticals LLC
 KP Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology KP Pharmaceuticals LLC is a pharmaceuticals company which develops, manufactures, markets and sells branded prescription pharmaceutical products. The company was founded by John M. Gregory, Randal J. Kirk, Joseph R. Gregory, Jefferson J. Gregory and James E. Gregory in 1993 and is is headquartered in Bristol, TN. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Serenex, Inc.
 Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Health Technology |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Icagen, Inc.
 Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
ViiV Healthcare Ltd.
 ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |
New Rhein Healthcare Investors
New Rhein Healthcare Investors Investment ManagersFinance New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | Finance |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | Health Technology |
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |
Panacea Acquisition Corp. II
 Panacea Acquisition Corp. II Financial ConglomeratesFinance Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA. | Finance |
- Borsa valori
- Insiders
- Douglas Giordano
